Unattributed Code Systems

• http://snomed.info/sct
• http://unstats.un.org/unsd/methods/m49/m49.htm

Copyright Fragment

This fragment is not visible to the reader

Copyright and Registered Trademark Uses

• IG © 2020+ HL7 International - Vocabulary Work Group. Package hl7.terminology#6.3.0 based on FHIR 5.0.0. Generated 2025-04-28 Links: Table of Contents | QA Report | Version History external | external | Propose a change external ( src )
• "compose" : { "include" : [{ // only modifiers "system" : "http://www.ama-assn.org/go/cpt", "copyright" : "CPT © Copyright 2023 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.", "filter" : [{ "property" : "modifier", "op" : "=", "value" : "true" }] }] } ( src )
• "compose" : { "include" : [{ // plain codes (no modifiers) "system" : "http://www.ama-assn.org/go/cpt", "copyright" : "CPT © Copyright 2023 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.", "filter" : [{ "property" : "modified", "op" : "=", "value" : "false" },{ "property" : "modifier", "op" : "=", "value" : "false" }] },{ // codes with modifiers (grammar enforces rules) "system" : "http://www.ama-assn.org/go/cpt", "filter" : [{ "property" : "modified", "op" : "=", "value" : "true" }] }] } ( src )
• "compose" : { "include" : [{ // plain codes (no modifiers) "system" : "http://www.ama-assn.org/go/cpt", "copyright" : "CPT © Copyright 2023 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.", "filter" : [{ "property" : "modified", "op" : "=", "value" : "false" },{ "property" : "modifier", "op" : "=", "value" : "false" }] }] } ( src )
• "compose" : { "include" : [{ "system" : "http://www.ama-assn.org/go/cpt", "copyright" : "CPT © Copyright 2023 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association." }] } ( src )
• <copyright value="This material contains content from LOINC (http://loinc.org). Refer to terminology.hl7.org for copyright information. LOINC® is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc."/> ( src )
• hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )
• 11.2513 Current Procedural Terminology (CPT®) ( src )
• 11.3723 Current Procedural Terminology (CPT®) ( src )
• "GS1®, under its IP Policy, seeks to avoid uncertainty regarding intellectual property claims by requiring the participants in the Work Group that developed this Healthcare GLN Implementation Guideline to agree to grant to GS1 members a royalty-free licence or a RAND licence to Necessary Claims, as that term is defined in the GS1 IP Policy. Furthermore, attention is drawn to the possibility that an implementation of one or more features of this Specification may be the subject of a patent or other intellectual property right that does not involve a Necessary Claim. Any such patent or other intellectual property right is not subject to the licensing obligations of GS1. Moreover, the agreement to grant licences provided under the GS1 IP Policy does not include IP rights and any claims of third parties who were not participants in the Work Group. ( src )
• "The Dun & Bradstreet D-U-N-S® Number (short for Data Universal Numbering System) is a nine-digit unique identifier for businesses. Hundreds of millions of D-U-N-S Numbers exist for companies across the globe. ( src )
• "The Dun & Bradstreet D-U-N-S® Number (short for Data Universal Numbering System) is a nine-digit unique identifier for businesses. Hundreds of millions of D-U-N-S Numbers exist for companies across the globe. A D-U-N-S Number is assigned through our patented identity resolution process, (part of our DUNSRight™ data governance, which includes thousands of separate automated checks.) The D-U-N-S Number identifies a company as being unique from any other in the Dun & Bradstreet Data Cloud. It is used as the starting point for any company's Live Business Identity, which helps ensure you have the most accurate and up-to-date view of organizations." For more information, see https://www.dnb.com/duns.html. ( src )
• "This material contains content from the pan-Canadian LOINC® Observation Code Database (pCLOCD). Canada Health Infoway Inc. (Infoway) has created pCLOCD from LOINC® to address local requirements in Canada. Infoway maintains the copyright on these localized additions. pCLOCD is available at no cost to users with Standards Access. Access to pan-Canadian standards and supporting information is available to anyone who accepts the applicable license agreements annually. Link to pCLOCD Terms of Use is https://infocentral.infoway-inforoute.ca/8_UserReferencesAndSupports/Terms_And_License_Agreements/pCLOCD_Terms_of_Use. This material also includes a portion of the LOINC table and is subject to a license from Regenstrief Institute, Inc. which is available at http://loinc.org/terms-of-use." ( src )
• "We (RSNA) recognize the benefits that come from radiologists using common language to communicate diagnostic results. For this reason, RSNA produced RadLex®, a comprehensive set of radiology terms for use in radiology reporting, decision support, data mining, data registries, education and research. ( src )
• **Definition:** an association between two Entities where the playing Entity (the part) is a component of the whole (scoper) in the sense of an integral structural component, that is distinct from other parts in the same whole, has a distinct function in the whole, and, as an effect, the full integrity of the whole depends (to some degree) on the presence of this part, even though the part may often be separable from the whole.**Discussion:** Part is defined in opposition to (a) ingredient (not separable), (b) content (not a functional component), and (c) member (not functionally distinct from other members). ( src )
• : Current Procedural Terminology (CPT®) - JSON Representation ( src )
• : Current Procedural Terminology (CPT®) - TTL Representation ( src )
• : Current Procedural Terminology (CPT®) - XML Representation ( src )
• A HIPAA Authorization must comply with 45 CFR Section164.508(c) Implementation specifications: Core elements and requirements - (1) Core elements. A valid authorization under this Section must contain at least the following elements: (i) A description of the information to be used or disclosed that identifies the information in a specific and meaningful fashion. (ii) The name or other specific identification of the person(s), or class of persons, authorized to make the requested use or disclosure. (iii) The name or other specific identification of the person(s), or class of persons, to whom the covered entity may make the requested use or disclosure. (iv) A description of each purpose of the requested use or disclosure. The statement "at the request of the individual" is a sufficient description of the purpose when an individual initiates the authorization and does not, or elects not to, provide a statement of the purpose. (v) An expiration date or an expiration event that relates to the individual or the purpose of the use or disclosure. The statement "end of the research study," "none," or similar language is sufficient if the authorization is for a use or disclosure of protected health information for research, including for the creation and maintenance of a research database or research repository. (vi) Signature of the individual and date. If the authorization is signed by a personal representative of the individual, a description of such representative's authority to act for the individual must also be provided. (2)Required statements. In addition to the core elements, the authorization must contain statements adequate to place the individual on notice of all of the following: (i) The individual's right to revoke the authorization in writing, and either: (A) The exceptions to the right to revoke and a description of how the individual may revoke the authorization; or (B) To the extent that the information in paragraph (c)(2)(i)(A) of this section is included in the notice required by Section 164.520, a reference to the covered entity's notice. https://www.gpo.gov/fdsys/pkg/CFR-2017-title45-vol1/pdf/CFR-2017-title45-vol1-sec164-508.pdf ( src )
• A code representing Title 38 Section 7332, which is a US Federal law stipulating the privacy rights of veterans diagnosed and treated for substance use disorders, infection with the human immunodeficiency virus, or sickle cell anemia. Title 38 Section 7332 - Confidentiality of certain medical records https://www.gpo.gov/fdsys/granule/USCODE-2011-title38/USCODE-2011-title38-partV-chap73-subchapIII-sec7332/content-detail.html (1) Records of the identity, diagnosis, prognosis, or treatment of any patient or subject which are maintained in connection with the performance of any program or activity (including education, training, treatment, rehabilitation, or research) relating to drug abuse, alcoholism or alcohol abuse, infection with the human immunodeficiency virus, or sickle cell anemia which is carried out by or for the Department under this title shall, except as provided in subsections (e) and (f), be confidential, and (section 5701 of this title to the contrary notwithstanding) such records may be disclosed only for the purposes and under the circumstances expressly authorized under subsection (b). (2) Paragraph (1) prohibits the disclosure to any person or entity other than the patient or subject concerned of the fact that a special written consent is required in order for such records to be disclosed. (b) (1) The content of any record referred to in subsection (a) may be disclosed by the Secretary in accordance with the prior written consent of the patient or subject with respect to whom such record is maintained, but only to such extent, under such circumstances, and for such purposes as may be allowed in regulations prescribed by the Secretary. (2) Whether or not any patient or subject, with respect to whom any given record referred to in subsection (a) is maintained, gives written consent, the content of such record may be disclosed by the Secretary as follows: (A) To medical personnel to the extent necessary to meet a bona fide medical emergency. (B) To qualified personnel for the purpose of conducting scientific research, management audits, financial audits, or program evaluation, but such personnel may not identify, directly or indirectly, any individual patient or subject in any report of such research, audit, or evaluation, or otherwise disclose patient or subject identities in any manner. (C) (i) In the case of any record which is maintained in connection with the performance of any program or activity relating to infection with the human immunodeficiency virus, to a Federal, State, or local public-health authority charged under Federal or State law with the protection of the public health, and to which Federal or State law requires disclosure of such record, if a qualified representative of such authority has made a written request that such record be provided as required pursuant to such law for a purpose authorized by such law. (ii) A person to whom a record is disclosed under this paragraph may not redisclose or use such record for a purpose other than that for which the disclosure was made. (D) If authorized by an appropriate order of a court of competent jurisdiction granted after application showing good cause therefor. In assessing good cause the court shall weigh the public interest and the need for disclosure against the injury to the patient or subject, to the physician-patient relationship, and to the treatment services. Upon the granting of such order, the court, in determining the extent to which any disclosure of all or any part of any record is necessary, shall impose appropriate safeguards against unauthorized disclosure. (E) To an entity described in paragraph (1)(B) of section 5701(k) of this title, but only to the extent authorized by such section. (F) (i) To a representative of a patient who lacks decision-making capacity, when a practitioner deems the content of the given record necessary for that representative to make an informed decision regarding the patient’s treatment. (ii) In this subparagraph, the term “representative” means an individual, organization, or other body authorized under section 7331 of this title and its implementing regulations to give informed consent on behalf of a patient who lacks decision-making capacity. (G) To a State controlled substance monitoring program, including a program approved by the Secretary of Health and Human Services under section 399O of the Public Health Service Act (42 U.S.C. 280g–3), to the extent necessary to prevent misuse and diversion of prescription medicines. (H) (i) To a non-Department entity (including private entities and other Federal agencies) for purposes of providing health care, including hospital care, medical services, and extended care services, to Veterans or performing other health care-related activities or functions. (ii) An entity to which a record is disclosed under this subparagraph may not disclose or use such record for a purpose other than that for which the disclosure was made or as permitted by law. (I) To a third party in order to recover or collect reasonable charges for care furnished to, or paid on behalf of, a Veteran in connection with a non-service connected disability as permitted by section 1729 of this title or for a condition for which recovery is authorized or with respect to which the United States is deemed to be a third party beneficiary under the Act entitled ‘An Act to provide for the recovery from tortiously liable third persons of the cost of hospital and medical care and treatment furnished by the United States’ (Public Law 87–693; 42 U.S.C. 2651 et seq.; commonly known as the ‘Federal Medical Care Recovery Act’). ( src )
• A displayed mark rendered to end users as a prescribed text warning that the electronic or hardcopy information shall not be further disclosed without consent of the subject of the information. For example, in order to warn a recipient of 42 CFR Part 2 information of the redisclosure restrictions, the rule mandates that end users receive a written prohibition against redisclosure unless authorized by patient consent or otherwise permitted by Part 2. See 42 CFR § 2.32 Prohibition on re-disclosure. (a)Notice to accompany disclosure. Each disclosure made with the patient's written consent must be accompanied by one of the following written statements: (1) This information has been disclosed to you from records protected by federal confidentiality rules ( 42 CFR part 2). The federal rules prohibit you from making any further disclosure of information in this record that identifies a patient as having or having had a substance use disorder either directly, by reference to publicly available information, or through verification of such identification by another person unless further disclosure is expressly permitted by the written consent of the individual whose information is being disclosed or as otherwise permitted by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose (see § 2.31). The federal rules restrict any use of the information to investigate or prosecute with regard to a crime any patient with a substance use disorder, except as provided at § § 2.12(c)(5) and 2.65; or (2) 42 CFR part 2 prohibits unauthorized disclosure of these records. https://www.law.cornell.edu/cfr/text/42/2.32 ( src )
• All non-trademark uses of the foregoing marks should include the ® symbol and indicate in text that: "HL7, FHIR and the FHIR [FLAME DESIGN] are the registered trademarks of Health Level Seven International and their use does not constitute endorsement by HL7." ( src )
• An authorization must specify a number of elements, including a description of the protected health information to be used and disclosed, the person authorized to make the use or disclosure, the person to whom the covered entity may make the disclosure, an expiration date, and, in some cases, the purpose for which the information may be used or disclosed. With limited exceptions, covered entities may not condition treatment or coverage on the individual providing an authorization. https://www.hhs.gov/hipaa/for-professionals/faq/264/what-is-the-difference-between-consent-and-authorization/index.html A HIPAA Authorization must comply with 45 CFR Section164.508(c) Implementation specifications: Core elements and requirements – (1) Core elements. A valid authorization under this Section must contain at least the following elements: (i) A description of the information to be used or disclosed that identifies the information in a specific and meaningful fashion. (ii) The name or other specific identification of the person(s), or class of persons, authorized to make the requested use or disclosure. (iii) The name or other specific identification of the person(s), or class of persons, to whom the covered entity may make the requested use or disclosure. (iv) A description of each purpose of the requested use or disclosure. The statement “at the request of the individual” is a sufficient description of the purpose when an individual initiates the authorization and does not, or elects not to, provide a statement of the purpose. (v) An expiration date or an expiration event that relates to the individual or the purpose of the use or disclosure. The statement “end of the research study,” “none,” or similar language is sufficient if the authorization is for a use or disclosure of protected health information for research, including for the creation and maintenance of a research database or research repository. (vi) Signature of the individual and date. If the authorization is signed by a personal representative of the individual, a description of such representative's authority to act for the individual must also be provided. (2)Required statements. In addition to the core elements, the authorization must contain statements adequate to place the individual on notice of all of the following: (i) The individual's right to revoke the authorization in writing, and either: (A) The exceptions to the right to revoke and a description of how the individual may revoke the authorization; or (B) To the extent that the information in paragraph (c)(2)(i)(A) of this section is included in the notice required by Section 164.520, a reference to the covered entity's notice. https://www.gpo.gov/fdsys/pkg/CFR-2017-title45-vol1/pdf/CFR-2017-title45-vol1-sec164-508.pdf ( src )
• Code system of concepts specifying the status of the patient's or the patient's representative's consent for responsibility to pay for potentially uninsured services. This element was introduced to satisfy CMS Medical Necessity requirements for outpatient services in the United States. Includes concepts such as (a) whether the associated diagnosis codes for the service are subject to medical necessity procedures, (b) whether, for this type of service, the patient has been informed that they may be responsible for payment for the service, and (c) whether the patient agrees to be billed for this service. Used in HL7 Version 2.x messaging in the ORC and FT1 segments. ( src )
• CodeSystem Current Procedural Terminology (CPT®) ( src )
• CodeSystem: Current Procedural Terminology (CPT®) ( src )
• CodeSystem: Current Procedural Terminology (CPT®) - Testing ( src )
• Confidentiality code total order hierarchy: Restricted (R) is less protective than V, and subsumes all other protection levels (i.e., N, M, L, and U). ( src )
• Copyright © 1989+ HL7. ( src )
• Copyright/Legal: (c) The OMOP Standardized Vocabularies Copyright Observational Health Data Sciences and Informatics, Columbia University, New York, NY. Licensed under Apache 2.0 ( src )
• Copyright/Legal: CPT © Copyright 2023 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. ( src )
• Copyright/Legal: Copyright © ICAO 2021. All rights reserved. None of the materials provided on this web site may be used, reproduced or transmitted, in whole or in part, in any form or by any means, electronic or mechanical, including photocopying, recording or the use of any information storage and retrieval system, except as provided for in the site Terms and Conditions without permission in writing from ICAO. ( src )
• Copyright/Legal: Dun & Bradstreet DUNS® Numbers are proprietary to and controlled by Dun & Bradstreet. Dun & Bradstreet grants you a non-exclusive, perpetual, limited license to use DUNS® Numbers (excluding linkage DUNS® Numbers) solely for identification purposes and only for your internal business use. Where practicable, you will refer to the number as a “DUNS® Number” and state that DUNS® is a registered trademark of Dun & Bradstreet. For more information, see https://www.dnb.com/utility-pages/terms-of-use.html ( src )
• Copyright/Legal: The UCUM codes, UCUM table (regardless of format), and UCUM Specification are copyright © 1999-2009, Regenstrief Institute, Inc. and the Unified Codes for Units of Measures (UCUM) Organization. All rights reserved. This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html. ( src )
• Copyright/Legal: These codes are excerpted from Digital Imaging and Communications in Medicine (DICOM) Standard, Part 16: Content Mapping Resource, Copyright © 2011 by the National Electrical Manufacturers Association. ( src )
• Copyright/Legal: This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license ( src )
• Copyright/Legal: This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html ( src )
• Copyright/Legal: This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html. This resource includes content from SNOMED Clinical Terms® (SNOMED CT®) which is copyright of the International Health Terminology Standards Development Organisation (IHTSDO). Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information contact http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org ( src )
• Copyright/Legal: This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license ( src )
• Copyright/Legal: This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html ( src )
• Copyright/Legal: This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html. ( src )
• Copyright/Legal: UCUM is Copyright © 1999-2013 Regenstrief Institute, Inc. and The UCUM Organization, Indianapolis, IN. All rights reserved. See http://unitsofmeasure.org/trac//wiki/TermsOfUse for details. This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html ( src )
• Current Procedural Terminology (CPT®) ( src )
• Current Procedural Terminology (CPT®) - HL7 Terminology (THO) v6.3.0 ( src )
• Current Procedural Terminology (CPT®) - JSON Representation - HL7 Terminology (THO) v6.3.0 ( src )
• Current Procedural Terminology (CPT®) - Resource Change History - HL7 Terminology (THO) v6.3.0 ( src )
• Current Procedural Terminology (CPT®) - TTL Representation - HL7 Terminology (THO) v6.3.0 ( src )
• Current Procedural Terminology (CPT®) - Testing - HL7 Terminology (THO) v6.3.0 ( src )
• Current Procedural Terminology (CPT®) - XML Representation - HL7 Terminology (THO) v6.3.0 ( src )
• Discussion: Part is defined in opposition to (a) ingredient (not separable), (b) content (not a functional component), and (c) member (not functionally distinct from other members). ( src )
• Dun & Bradstreet DUNS® Numbers are proprietary to and controlled by Dun & Bradstreet. Dun & Bradstreet grants you a non-exclusive, perpetual, limited license to use DUNS® Numbers (excluding linkage DUNS® Numbers) solely for identification purposes and only for your internal business use. Where practicable, you will refer to the number as a “DUNS® Number” and state that DUNS® is a registered trademark of Dun & Bradstreet. For more information, see https://www.dnb.com/utility-pages/terms-of-use.html ( src )
• Expansion from tx.fhir.org based on codesystem Current Procedural Terminology (CPT®) version2023 ( src )
• Global Location Number (GLN) can be used by companies to identify their locations, giving them complete flexibility to identify any type or level of location required. For more information as to how GLNs are used in healthcare, see a GS1 provided guide located here https://www.gs1.org/docs/healthcare/GLN_Healthcare_Imp_Guide.pdf For additional information regarding the GLN standard refer to the GS1 General Specifications (https://www.gs1.org/standards/barcodes-epcrfid-id-keys/gs1-general-specifications) and for assignment refer to the GS1 GLN Allocation Rules (https://www.gs1.org/1/glnrules/en/). GS1 local offices handle all enquiries related to GS1 standards. Please see the list of GS1 offices (https://www.gs1.org/contact/overview) for more information. In relation to the "Healthcare GLN Implementation Guideline": "GS1®, under its IP Policy, seeks to avoid uncertainty regarding intellectual property claims by requiring the participants in the Work Group that developed this Healthcare GLN Implementation Guideline to agree to grant to GS1 members a royalty-free licence or a RAND licence to Necessary Claims, as that term is defined in the GS1 IP Policy. Furthermore, attention is drawn to the possibility that an implementation of one or more features of this Specification may be the subject of a patent or other intellectual property right that does not involve a Necessary Claim. Any such patent or other intellectual property right is not subject to the licensing obligations of GS1. Moreover, the agreement to grant licences provided under the GS1 IP Policy does not include IP rights and any claims of third parties who were not participants in the Work Group. Accordingly, GS1 recommends that any organisation developing an implementation designed to be in conformance with this Specification should determine whether there are any patents that may encompass a specific implementation that the organisation is developing in compliance with the Specification and whether a licence under a patent or other intellectual property right is needed. Such a determination of a need for licencing should be made in view of the details of the specific system designed by the organisation in consultation with their own patent counsel." "GS1 disclaims all liability for any damages arising from use or misuse of this document, whether special, indirect, consequential, or compensatory damages, and including liability for infringement of any intellectual property rights, relating to use of information in or reliance upon this document." GS1 and the GS1 logo are registered trademarks of GS1 AISBL. ( src )
• HL7 Terminology (THO), published by HL7 International - Vocabulary Work Group. This guide is not an authorized publication; it is the continuous build for version 6.3.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/UTG/ and changes regularly. See the Directory of published versions ( src )
• HL7® (Health Level Seven, Inc.) Terminology Copyright and License ( src )
• HL7®, HEALTH LEVEL SEVEN®, FHIR® and the FHIR [image]® are trademarks owned by Health Level Seven International, registered with the United States Patent and Trademark Office. ( src )
• ICD-10 is ©Copyright World Health Organization (WHO). WHO licenses its published material widely, in order to encourage maximum use and dissemination. See Licensing WHO classifications for details. The ICD variants have their own separate copyright and licensing (refer to the documentation for the particular variant for details). ( src )
• ICNP(r) is a combinatorial terminology, using a multi-axial structure. ICNP(r) provides standardized terms and codes for terms in two classifications that can be used to compose or create pre-coordinated concepts to represent observations and procedures, specifically, patient problems/nursing diagnoses, nursing interventions including those focused on assessment and actual or expected (goal) outcomes. The ICNP(r) Classification for Nursing Phenomena is used to compose concepts or statements to represent observations (nursing diagnoses, patient problems, patient status, patient outcomes). The ICNP(r) Nursing Actions Classification is used to compose concepts or statements to represent procedures (nursing interventions) ( src )
• International Healthcare Terminology Standards Developing Organization (IHTSDO).This specification includes content from SNOMED CT, which is copyright © 2002+ International Health Terminology Standards Development Organisation (IHTSDO) and distributed by agreement between IHTSDO and HL7. Implementer use of SNOMED CT is not covered by this agreement ( src )
• Logical Observation Identifier Names and Codes (LOINC®) ( src )
• Logical Observation Identifiers Names and Codes (LOINC®) provides a set of universal codes and names for identifying laboratory and other clinical observations. One of the main goals of LOINC is to facilitate the exchange and pooling of results for clinical care, outcomes management, and research. LOINC was initiated by Regenstrief Institute research scientists who continue to develop it with the collaboration of the LOINC Committee. The LOINC table, LOINC codes, and LOINC panels and forms file are copyright © 1995-2011, Regenstrief Institute, Inc. and the LOINC Committee and available at no cost (http://loinc.org) under the license at http://loinc.org/terms-of-use. The laboratory portion of the LOINC database contains the usual clinical laboratory categories of chemistry, hematology, serology, microbiology (including parasitology and virology), toxicology; as well as categories for drugs and the cell counts, antibiotic susceptibilities, and more. The clinical portion of the LOINC database includes entries for vital signs, hemodynamics, intake/output, EKG, obstetric ultrasound, cardiac echo, radiology report titles, pulmonary ventilator management, document and section titles, patient assessment instruments (e.g. Glascow Coma Score, PHQ-9 depression scale, CMS-required patient assessment instruments), and other clinical observations. ( src )
• NamingSystem Current Procedural Terminology (CPT®) ( src )
• NamingSystem: Current Procedural Terminology (CPT®) ( src )
• NamingSystem: Current Procedural Terminology (CPT®) - Testing ( src )
• Placer Applications. In response to a Filler application requesting refill authorization (RF), DF indicates that the placer does not authorize refills for the order. ORC-16 Order Control Code reason may be used to indicate the reason for the request denial. Some suggested values include: AA Patient unknown to the provider AB Patient never under provider care AC Patient no longer under provider care AD Patient has requested refill too soon AE Medication never prescribed for the patient AF Patient should contact provider first AG Refill not appropriate Note that these values originate from the NCPDP SCRIPT Response Segment Code List Qualifiers. Materials Reproduced with the consent of ©National Council for Prescription Drug Programs, Inc. 1988, 1992, 2002 NCPDP. ( src )
• Privacy metadata indicating the level of protection required to safeguard potentially stigmatizing information, which if disclosed without authorization, would present a high risk of harm to an individual's reputation and sense of privacy.*Usage Note:* The level of protection afforded restricted confidential information is dictated by specially protective organizational or jurisdictional privacy policies, including at an authorized individual's request, intended to engender patient trust in providers of sensitive services.Privacy policies mandating additional levels of protection by restricting information access preempt less protective privacy policies when the information is used in the delivery and management of healthcare. May be pre-empted by jurisdictional law (e.g., for public health reporting or emergency treatment).Confidentiality code total order hierarchy: Restricted (R) is less protective than *V*, and subsumes all other protection levels (i.e., *N, M, L, and U*).**Examples:** Includes information that is additionally protected such as sensitive conditions mental health, HIV, substance abuse, domestic violence, child abuse, genetic disease, and reproductive health; or sensitive demographic information such as a patient's standing as an employee or a celebrity. May be used to indicate proprietary or classified information that is not related to an individual (e.g., secret ingredients in a therapeutic substance; or the name of a manufacturer). ( src )
• RadLex is a comprehensive set of radiology terms for use in radiology reporting, decision support, data mining, data registries, education and research. RadLex Playbook is a project of the Radiological Society of North America (RSNA), and constitutes a portion of the RadLex ontology. Playbook aims to provide a standard system for naming radiology procedures, based on the elements which define an imaging exam such as modality and body part. By providing standard names and codes for radiologic studies, Playbook is intended to facilitate a variety of operational and quality improvement efforts, including workflow optimization, chargemaster management, radiation dose tracking, enterprise integration and image exchange. As of RadLex Playbook version 2.5, a four-year project to harmonize RadLex Playbook with the radiology portion of the LOINC standard has been concluded, leading to the LOINC-RSNA Radiology Playbook which is jointly managed by the Regenstrief Institute (publisher of LOINC) and RSNA. This harmonized Playbook defines a new information model for describing imaging procedures, and identifies correspondences between RadLex Playbook codes and LOINC codes. (See https://loinc.org/download/loinc-users-guide and http://pubs.rsna.org/doi/pdf/10.1148/rg.2017160188 for details.) Note that RadLex Playbook codes start with "RPID" followed by a numerical value. LOINC codes consist of a numerical code, followed by a hyphen and a single additional digit (called the check digit). Note that in the future, new codes will be created in the LOINC format only, not the RPID format. New adopters are encouraged to use LOINC-format codes. LOINC-format codes may be accessed at http://search.loinc.org. New code requests may be submitted to the joint Regenstrief-RSNA governance committee at https://loinc.org/submissions/. From the RSNA website: "We (RSNA) recognize the benefits that come from radiologists using common language to communicate diagnostic results. For this reason, RSNA produced RadLex®, a comprehensive set of radiology terms for use in radiology reporting, decision support, data mining, data registries, education and research. RadLex provides the foundation for vital data resources used in radiology: ( src )
• Regenstrief Institute provides access to LOINC's terminology content through the HL7® FHIR® API. See the LOINC FHIR Terminology Server page for details. ( src )
• SNOMED CT is © and ® SNOMED International. The right to maintain the GPS remains vested exclusively in SNOMED International. ( src )
• SNOMED CT® was originally created by the College of American Pathologists. ( src )
• Section 1886(d) of the Act specifies that the Secretary shall establish a classification system (referred to as DRGs) for inpatient discharges and adjust payments under the IPPS based on appropriate weighting factors assigned to each DRG. Therefore, under the IPPS, we[CMS] pay for inpatient hospital services on a rate per discharge basis that varies according to the DRG to which a beneficiary's stay is assigned. The formula used to calculate payment for a specific case multiplies an individual hospital's payment rate per case by the weight of the DRG to which the case is assigned. Each DRG weight represents the average resources required to care for cases in that particular DRG, relative to the average resources used to treat cases in all DRGs. Congress recognized that it would be necessary to recalculate the DRG relative weights periodically to account for changes in resource consumption. Accordingly, section 1886(d)(4)(C) of the Act requires that the Secretary adjust the DRG classifications and relative weights at least annually. These adjustments are made to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. ( src )
• Section 1886(d) of the Act specifies that the Secretary shall establish a classification system (referred to as DRGs) for inpatient discharges and adjust payments under the IPPS based on appropriate weighting factors assigned to each DRG. Therefore, under the IPPS, we[CMS] pay for inpatient hospital services on a rate per discharge basis that varies according to the DRG to which a beneficiary's stay is assigned. The formula used to calculate payment for a specific case multiplies an individual hospital's payment rate per case by the weight of the DRG to which the case is assigned. Each DRG weight represents the average resources required to care for cases in that particular DRG, relative to the average resources used to treat cases in all DRGs. Congress recognized that it would be necessary to recalculate the DRG relative weights periodically to account for changes in resource consumption. Accordingly, section 1886(d)(4)(C) of the Act requires that the Secretary adjust the DRG classifications and relative weights at least annually. These adjustments are made to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. Currently, cases are classified into Medicare Severity Diagnosis Related Groups (MS-DRGs) for payment under the IPPS based on the following information reported by the hospital: the principal diagnosis, up to 25 additional diagnoses, and up to 25 procedures performed during the stay. In a small number of MS-DRGs, classification is also based on the age, sex, and discharge status of the patient. Effective October 1, 2015, the diagnosis and procedure information is reported by the hospital using codes from the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) and the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS). Content can be obtained on the CMS hosted page located at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software The DRGs are released annually with errata published infrequently. The fiscal year and release version should be noted (e.g., 2021.38.R1). Requests for annual MS-DRG classification changes and any MS-DRG related inquiries should be sent to the MSDRGClassificationChange@cms.hhs.gov mailbox. For additional information on the MS-DRG system, including yearly reviews and changes to the MS-DRGs, please view prior Inpatient Prospective Payment System (IPPS) proposed and final rules located in the left navigational area of https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software ( src )
• See 45 CFR 164.524(c)(3)(ii) If an individual's request for access directs the covered entity to transmit the copy of protected health information directly to another person designated by the individual, the covered entity must provide the copy to the person designated by the individual. The individual's request must be in writing, signed by the individual, and clearly identify the designated person and where to send the copy of protected health information. https://www.gpo.gov/fdsys/pkg/CFR-2017-title45-vol1/pdf/CFR-2017-title45-vol1-sec164-524.pdf ( src )
• See 45 CFR 164.524(c)(3)(ii) If an individual's request for access directs the covered entity to transmit the copy of protected health information directly to another person designated by the individual, the covered entity must provide the copy to the person designated by the individual. The individual's request must be in writing, signed by the individual, and clearly identify the designated person and where to send the copy of protected health information. https://www.gpo.gov/fdsys/pkg/CFR-2017-title45-vol1/pdf/CFR-2017-title45-vol1-sec164-524.pdf ( src )
• See Section 164.508 Uses and disclosures for which an authorization is required. (2)Authorization required: Psychotherapy notes https://www.gpo.gov/fdsys/pkg/CFR-2017-title45-vol1/pdf/CFR-2017-title45-vol1-sec164-508.pdf: Notwithstanding any provision of this subpart, other than the transition provisions in Section 164.532, a covered entity must obtain an authorization for any use or disclosure of psychotherapy notes, except: (i) To carry out the following treatment, payment, or health care operations: (A) Use by the originator of the psychotherapy notes for treatment; (B) Use or disclosure by the covered entity for its own training programs in which students, trainees, or practitioners in mental health learn under supervision to practice or improve their skills in group, joint, family, or individual counseling; or (C) Use or disclosure by the covered entity to defend itself in a legal action or other proceeding brought by the individual; and (ii) A use or disclosure that is required by Section 164.502(a)(2)(ii) or permitted by Section 164.512(a); Section 164.512(d) with respect to the oversight of the originator of the psychotherapy notes; Section 164.512(g)(1); Section 164.512(j)(1)(i). ( src )
• See Section 164.508 Uses and disclosures for which an authorization is required. (2)Authorization required: Psychotherapy notes https://www.gpo.gov/fdsys/pkg/CFR-2017-title45-vol1/pdf/CFR-2017-title45-vol1-sec164-508.pdf: Notwithstanding any provision of this subpart, other than the transition provisions in Section 164.532, a covered entity must obtain an authorization for any use or disclosure of psychotherapy notes, except: (i) To carry out the following treatment, payment, or health care operations: (A) Use by the originator of the psychotherapy notes for treatment; (B) Use or disclosure by the covered entity for its own training programs in which students, trainees, or practitioners in mental health learn under supervision to practice or improve their skills in group, joint, family, or individual counseling; or (C) Use or disclosure by the covered entity to defend itself in a legal action or other proceeding brought by the individual; and (ii) A use or disclosure that is required by Section 164.502(a)(2)(ii) or permitted by Section 164.512(a); Section 164.512(d) with respect to the oversight of the originator of the psychotherapy notes; Section 164.512(g)(1); Section 164.512(j)(1)(i). ( src )
• Some content from IHE® Copyright © 2015 IHE International, Inc. The IHE concepts are from the IHE Technical Frameworks and Supplements, available for free download and use at http://www.ihe.net/Technical_Frameworks/ ( src )
• Staged or Related Procedure or Service by the Same Physician or Other Qualified Health Care Professional During the Postoperative Period: It may be necessary to indicate that the performance of a procedure or service during the postoperative period was: (a) planned or anticipated (staged); (b) more extensive than the original procedure; or (c) for therapy following a surgical procedure. This circumstance may be reported by adding modifier 58 to the staged or related procedure. Note: For treatment of a problem that requires a return to the operating/procedure room (eg, unanticipated clinical condition), see modifier 78 ( src )
• Table of codes specifying the status of the patient's or the patient's representative's consent for responsibility to pay for potentially uninsured services. This element was introduced to satisfy CMS Medical Necessity requirements for outpatient services in the United States. Includes concepts such as (a) whether the associated diagnosis codes for the service are subject to medical necessity procedures, (b) whether, for this type of service, the patient has been informed that they may be responsible for payment for the service, and (c) whether the patient agrees to be billed for this service. ( src )
• The FHIR R5 specification includes content from SNOMED Clinical Terms® (SNOMED CT®) is copyright of the International Health Terminology Standards Development Organisation (IHTSDO) (trading as SNOMED International). Implementers of these specifications must have the appropriate SNOMED CT Affiliate license - for more information access http://www.snomed.org/snomed-ct/get-snomed-ct or contact SNOMED International via email at info@snomed.org. ( src )
• The HL7 Terminology is produced by HL7 under the terms of HL7® Governance and Operations Manual relating to Intellectual Property (Section 09, at the time of this publication), specifically its copyright, trademark, and patent provisions. ( src )
• The HL7®(Health Level Seven, Inc.) Terminology content developed by HL7 are derived from the collective experience of the HL7 membership and community feedback from the development and application of a spectrum of health care interoperability solutions. However, because HL7 Terminology supports multiple contexts of use, it is the responsibility of the persons or organizations using this content to ensure their use is fit for their particular purpose, including validation for clinical and operational use. ( src )
• The SNODENT identifiers for all of the possible human teeth, both adult and adolescent. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for dental anterior inter-arch deviations utilized to calculate the Salzmann Malocclusion Severity Index. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for dental posterior inter-arch deviations utilized to calculate the Salzmann Malocclusion Severity Index. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for gross patient findings that inform the course of orthodontic treatment to be performed. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for patient conditions that may preclude starting orthodontic treatment. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for regions in the mouth utilized to calculate the Salzmann Malocclusion Severity Index. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the most common craniofacial anomalies that may influence the course of orthodontic treatment to be performed. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the recognized grades of tooth mobility according to the Miller Classification system. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the regions of the human frenum within the mouth. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the relative location of a human tooth root that is being observed for furcation. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the relative positions around the tooth that are probed and measured in assessing a patient's periodontal health. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the stages of dentition an individual progresses through during a lifetime. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the teeth in the maxilla assessed for tooth-specific inter-arch deviations as part of calculating the Salzmann Malocclusion Severity Index. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for the two jaws (mandible and maxilla). This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The SNODENT identifiers for tooth-specific abnormalities that impact orthodontic treatment. This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. http://www.ada.org/en/member-center/member-benefits/practice-resources/dental-informatics/snodent/licensing-snodent Steward: Attachments WG ( src )
• The description is based on the following GDPR provisions: Article 6.1.c https://gdpr-info.eu/art-6-gdpr/ 1Processing shall be lawful only if and to the extent that at least one of the following applies: (c) processing is necessary for compliance with a legal obligation to which the controller is subject. Article 9.1, 9.2.b https://gdpr-info.eu/art-9-gdpr/ 1. Processing of personal data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and the processing of genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation shall be prohibited. 2. Paragraph 1 shall not apply if one of the following applies: (b) processing is necessary for the purposes of carrying out the obligations and exercising specific rights of the controller or of the data subject in the field of employment and social security and social protection law in so far as it is authorised by Union or Member State law or a collective agreement pursuant to Member State law providing for appropriate safeguards for the fundamental rights and the interests of the data subject. ( src )
• The description is based on the following GDPR provisions: Article 6.1.d https://gdpr-info.eu/art-6-gdpr/ 1Processing shall be lawful only if and to the extent that at least one of the following applies: (d) processing is necessary in order to protect the vital interests of the data subject or of another natural person. Article 9.1, and 9.2.c and 9.2.h, 9.3 https://gdpr-info.eu/art-9-gdpr/ 1. Processing of personal data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and the processing of genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation shall be prohibited. 2. Paragraph 1 shall not apply if one of the following applies: (c) processing is necessary to protect the vital interests of the data subject or of another natural person where the data subject is physically or legally incapable of giving consent; (h) processing is necessary for the purposes of preventive or occupational medicine, for the assessment of the working capacity of the employee, medical diagnosis, the provision of health or social care or treatment or the management of health or social care systems and services on the basis of Union or Member State law or pursuant to contract with a health professional and subject to the conditions and safeguards referred to in paragraph 3; 3. Personal data referred to in paragraph 1 may be processed for the purposes referred to in point (h) of paragraph 2 when those data are processed by or under the responsibility of a professional subject to the obligation of professional secrecy under Union or Member State law or rules established by national competent bodies or by another person also subject to an obligation of secrecy under Union or Member State law or rules established by national competent bodies. ( src )
• The domain of possible values for the status of the patient's or the patient's representative's consent for responsibility to pay for potentially uninsured services. This element was introduced to satisfy CMS Medical Necessity requirements for outpatient services in the United States. Includes concepts such as (a) whether the associated diagnosis codes for the service are subject to medical necessity procedures, (b) whether, for this type of service, the patient has been informed that they may be responsible for payment for the service, and (c) whether the patient agrees to be billed for this service. ( src )
• The pan Canadian LOINC Observation Code Database (pCLOCD) is the Canadian version of the LOINC(tm) database. It was created using the LOINC(tm) records and attributes that were constrained for Canadian use and supplemented to specifically meet Canadian requirements. It contains the core LOINC(tm) attributes as required by Regenstrief copyright rules. The LOINC(tm) Component has been customized to meet Canadian requirements and is displayed as the pan Canadian Component Name. This component name is the basis for the pan Canadian Display Name. Core attributes are include both English and Canadian French. ( src )
• The pan Canadian LOINC Observation Code Database (pCLOCD) is the Canadian version of the LOINC(tm) database. It was created using the LOINC(tm) records and attributes that were constrained for Canadian use and supplemented to specifically meet Canadian requirements. It contains the core LOINC(tm) attributes as required by Regenstrief copyright rules. The LOINC(tm) Component has been customized to meet Canadian requirements and is displayed as the pan Canadian Component Name. This component name is the basis for the pan Canadian Display Name. Core attributes are include both English and Canadian French. This code system contains supplemental "X" codes defined in the pCLOCD that do not yet exist in the LOINC code system. ( src )
• This material contains content from LOINC (http://loinc.org). LOINC is copyright © 1995-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC® is a registered United States trademark of Regenstrief Institute, Inc. ( src )
• This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html ( src )
• This page describes the license terms for everything contained in these HL7 Terminology pages that has been developed by HL7®(Health Level Seven, Inc.), but does not include any content developed by third parties that may be available on these pages. ( src )
• This processing policy code offers an escape-hatch to countries like Denmark and Austria: they simply declare their national healthcare data exchanges to be necessary for the management of their healthcare system. This allows them to establish an opt-out mechanism under the GDPR, whereas normally GDPR would be opt-in when it comes to such national exchanges. The description is based on the following GDPR provisions: Article 9.1, and 9.2.c and 9.2.h, 9.3 https://gdpr-info.eu/art-9-gdpr/ 1. Processing of personal data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and the processing of genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation shall be prohibited. 2. Paragraph 1 shall not apply if one of the following applies: (c) processing is necessary to protect the vital interests of the data subject or of another natural person where the data subject is physically or legally incapable of giving consent; (h) processing is necessary for the purposes of preventive or occupational medicine, for the assessment of the working capacity of the employee, medical diagnosis, the provision of health or social care or treatment or the management of health or social care systems and services on the basis of Union or Member State law or pursuant to contract with a health professional and subject to the conditions and safeguards referred to in paragraph 3; 3. Personal data referred to in paragraph 1 may be processed for the purposes referred to in point (h) of paragraph 2 when those data are processed by or under the responsibility of a professional subject to the obligation of professional secrecy under Union or Member State law or rules established by national competent bodies or by another person also subject to an obligation of secrecy under Union or Member State law or rules established by national competent bodies. ( src )
• This value set contains content from SNODENT® Copyright American Dental Association (ADA). All rights reserved. SNODENT is a registered trademark of the ADA. ( src )
• UCUM is Copyright © 1999-2013 Regenstrief Institute, Inc. and The UCUM Organization, Indianapolis, IN. All rights reserved. See TermsOfUse for details. ( src )
• When Value Sets include CPT codes, the ValueSet.compose.include.copyright element should have the text "CPT © Copyright 2023 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.". The year in the copyright element should be adjusted to reflect the release year(s) being used. ( src )
• When referencing the FHIR® standard in a website, document, presentation, or otherwise, please in a place of prominence refer to it as the "HL7® FHIR® standard". In subsequent uses, please refer to it as the "FHIR® standard" or "FHIR®", using the ® symbol as often as is practical, at least once on each page of printed matter, generally in connection with the first or dominant usage. ( src )
• When using the [image] logo, always include the ® symbol ( src )
• https://www.gpo.gov/fdsys/granule/USCODE-2011-title38/USCODE-2011-title38-partV-chap73-subchapIII-sec7332/content-detail.html . (1) Records of the identity, diagnosis, prognosis, or treatment of any patient or subject which are maintained in connection with the performance of any program or activity (including education, training, treatment, rehabilitation, or research) relating to drug abuse, alcoholism or alcohol abuse, infection with the human immunodeficiency virus, or sickle cell anemia which is carried out by or for the Department under this title shall, except as provided in subsections (e) and (f), be confidential, and (section 5701 of this title to the contrary notwithstanding) such records may be disclosed only for the purposes and under the circumstances expressly authorized under subsection (b). (2) Paragraph (1) prohibits the disclosure to any person or entity other than the patient or subject concerned of the fact that a special written consent is required in order for such records to be disclosed. (b) (1) The content of any record referred to in subsection (a) may be disclosed by the Secretary in accordance with the prior written consent of the patient or subject with respect to whom such record is maintained, but only to such extent, under such circumstances, and for such purposes as may be allowed in regulations prescribed by the Secretary. (2) Whether or not any patient or subject, with respect to whom any given record referred to in subsection (a) is maintained, gives written consent, the content of such record may be disclosed by the Secretary as follows: (A) To medical personnel to the extent necessary to meet a bona fide medical emergency. (B) To qualified personnel for the purpose of conducting scientific research, management audits, financial audits, or program evaluation, but such personnel may not identify, directly or indirectly, any individual patient or subject in any report of such research, audit, or evaluation, or otherwise disclose patient or subject identities in any manner. (C) (i) In the case of any record which is maintained in connection with the performance of any program or activity relating to infection with the human immunodeficiency virus, to a Federal, State, or local public-health authority charged under Federal or State law with the protection of the public health, and to which Federal or State law requires disclosure of such record, if a qualified representative of such authority has made a written request that such record be provided as required pursuant to such law for a purpose authorized by such law. (ii) A person to whom a record is disclosed under this paragraph may not redisclose or use such record for a purpose other than that for which the disclosure was made. (D) If authorized by an appropriate order of a court of competent jurisdiction granted after application showing good cause therefor. In assessing good cause the court shall weigh the public interest and the need for disclosure against the injury to the patient or subject, to the physician-patient relationship, and to the treatment services. Upon the granting of such order, the court, in determining the extent to which any disclosure of all or any part of any record is necessary, shall impose appropriate safeguards against unauthorized disclosure. (E) To an entity described in paragraph (1)(B) of section 5701(k) of this title, but only to the extent authorized by such section. (F) (i) To a representative of a patient who lacks decision-making capacity, when a practitioner deems the content of the given record necessary for that representative to make an informed decision regarding the patient's treatment. (ii) In this subparagraph, the term "representative" means an individual, organization, or other body authorized under section 7331 of this title and its implementing regulations to give informed consent on behalf of a patient who lacks decision-making capacity. (G) To a State controlled substance monitoring program, including a program approved by the Secretary of Health and Human Services under section 399O of the Public Health Service Act (42 U.S.C. 280g-3), to the extent necessary to prevent misuse and diversion of prescription medicines. (H) (i) To a non-Department entity (including private entities and other Federal agencies) for purposes of providing health care, including hospital care, medical services, and extended care services, to Veterans or performing other health care-related activities or functions. (ii) An entity to which a record is disclosed under this subparagraph may not disclose or use such record for a purpose other than that for which the disclosure was made or as permitted by law. (I) To a third party in order to recover or collect reasonable charges for care furnished to, or paid on behalf of, a Veteran in connection with a non-service connected disability as permitted by section 1729 of this title or for a condition for which recovery is authorized or with respect to which the United States is deemed to be a third party beneficiary under the Act entitled 'An Act to provide for the recovery from tortiously liable third persons of the cost of hospital and medical care and treatment furnished by the United States' (Public Law 87-693; 42 U.S.C. 2651 et seq.; commonly known as the 'Federal Medical Care Recovery Act'). ( src )

External References

"The Dun & Bradstreet D-U-N-S® Number (short for Data Universal Numbering System) is a nine-digit unique identifier for businesses. Hundreds of millions of D-U-N-S Numbers exist for companies across the globe.

A D-U-N-S Number is assigned through our patented identity resolution process, (part of our DUNSRight™ data governance, which includes thousands of separate automated checks.) The D-U-N-S Number identifies a company as being unique from any other in the Dun & Bradstreet Data Cloud. It is used as the starting point for any company's Live Business Identity, which helps ensure you have the most accurate and up-to-date view of organizations."

For more information, see https://www.dnb.com/duns.html.